Many diseases are caused by insufficient expression of mutated genes and would benefit
from increased expression of the corresponding protein. However, in drug development, it …

Oligonucleotide-based therapeutics have attracted attention as an emerging modality that
includes the modulation of genes and their binding proteins related to diseases, allowing us …

Intracellular protein delivery is highly desirable for protein drug‐based cell therapy.
Established technologies suffer from poor cell‐specific cytosolic protein delivery, which …

The era of innovative RNA therapies using antisense oligonucleotides (ASOs), siRNAs, and
mRNAs is beginning. Since the emergence of the concept of ASOs in 1978, it took more than …

The potential of oligonucleotide therapeutics is undeniable as more than 15 drugs have
been approved to treat various diseases in the liver, central nervous system (CNS), and …

Locked nucleic acids (LNAs) are a subtype of antisense oligonucleotides (ASOs) that are
characterized by a bridge within the sugar moiety. LNAs owe their robustness to this …

Simple Summary Activated STAT3 is an essential factor in cancer development; therefore,
blocking STAT3 may be of therapeutic benefit in multiple cancer types. Thanks to recent …

Oligonucleotides hold great promise as therapeutic agents but poor bioavailability limits
their utility. Hence, new analogues with improved cell uptake are urgently needed. Here, we …

Polyanionic antisense oligonucleotides hold great promise as RNA targeting drugs but
issues with bioavailability hinder their development. Uncharged phosphorus-based …

Lung cancer is one of the most aggressive and deadliest health threats. There has been an
increasing interest in non-coding RNA (ncRNA) recently, especially in the areas of …